Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Rosner

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
Seminars in Arthritis and Rheumatism|February 1, 1995
Cancer-associated rheumatic disorders: clues to occult neoplasiaJ E Nashitz, I Rosner, M Rozenbaum, et al.
Annals of Biomedical Engineering|February 5, 2004
Rational design of contact guiding, neurotrophic matrices for peripheral nerve regenerationB I Rosner, R A Siegel, A Grosberg, et al.
Lupus|April 29, 2000
The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patientsE Toubi, I Rosner, M Rozenbaum, et al.
Seminars in Arthritis and Rheumatism|September 1, 1999
Rheumatic syndromes: clues to occult neoplasiaJ E Naschitz, I Rosner, M Rozenbaum, et al.
Clinical and Experimental Rheumatology|August 5, 2011
Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapyA Snir, A Kessel, T Haj, et al.
The CLAO Journal : Official Publication of the Contact Lens Association of Ophthalmologists, Inc|October 1, 1992
A retrospective study of disposable extended wear lenses in 100 patients: year 2E Maguen, I Rosner, P Caroline, et al.
Scandinavian Journal of Immunology|April 21, 2006
The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosusE Toubi, A Kessel, I Rosner, et al.
Medicine|January 1, 1996
The fasciitis-panniculitis syndromes. Clinical and pathologic featuresJ E Naschitz, J H Boss, I Misselevich, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 17, 2008
Paraneoplastic leukocytoclastic vasculitisM Rozenbaum, J E Naschitz, I Rosner, et al.
Clinical and Experimental Rheumatology|June 8, 2002
The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severityE Toubi, A Kessel, G Grushko, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Seminars in Arthritis and Rheumatism|February 1, 1995
Cancer-associated rheumatic disorders: clues to occult neoplasiaJ E Nashitz, I Rosner, M Rozenbaum, et al.
Annals of Biomedical Engineering|February 5, 2004
Rational design of contact guiding, neurotrophic matrices for peripheral nerve regenerationB I Rosner, R A Siegel, A Grosberg, et al.
Lupus|April 29, 2000
The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patientsE Toubi, I Rosner, M Rozenbaum, et al.
Seminars in Arthritis and Rheumatism|September 1, 1999
Rheumatic syndromes: clues to occult neoplasiaJ E Naschitz, I Rosner, M Rozenbaum, et al.
Clinical and Experimental Rheumatology|August 5, 2011
Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapyA Snir, A Kessel, T Haj, et al.
The CLAO Journal : Official Publication of the Contact Lens Association of Ophthalmologists, Inc|October 1, 1992
A retrospective study of disposable extended wear lenses in 100 patients: year 2E Maguen, I Rosner, P Caroline, et al.
Scandinavian Journal of Immunology|April 21, 2006
The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosusE Toubi, A Kessel, I Rosner, et al.
Medicine|January 1, 1996
The fasciitis-panniculitis syndromes. Clinical and pathologic featuresJ E Naschitz, J H Boss, I Misselevich, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 17, 2008
Paraneoplastic leukocytoclastic vasculitisM Rozenbaum, J E Naschitz, I Rosner, et al.
Clinical and Experimental Rheumatology|June 8, 2002
The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severityE Toubi, A Kessel, G Grushko, et al.
Pageof 13